Daily Brief Health Care: Lexaria Bioscience , Alcon , Arrowhead Pharmaceuticals , Cardinal Health, Hims & Hers Health Inc, Abbvie Inc, Ramkhamhaeng Hospital and more

• Disruptive Proprietary Platform for High-Value Oral Peptide Delivery: Lexaria Bioscience Corp. (LEXX) utilizes its patented DehydraTECH platform—now advanced to DehydraTECH 3.0—to significantly enhance the oral bioavailability, onset speed, and gastrointestinal tolerability of fat-soluble active pharmaceutical ingredients (APIs) and peptides, addressing a multi-billion-dollar commercial opportunity in oral GLP-1/GIP metabolic therapeutics.
• Substantial Preclinical and Clinical Validation: Preclinical and pilot clinical data demonstrate robust performance advantages, including up to a 5-fold increase in oral absorption for next-generation metabolic candidates such as amycretin and retatrutide, validating DehydraTECH as an out-licensing candidate for global pharmaceutical partners seeking needle-free delivery alternatives.
• Fortified Non-Dilutive Capital and Asset-Light Licensing Model: Supported by an Australian Tax Office R&D cash rebate of AUD$3.67 million (~USD$2.6 million), recent warrant exercises, and a zero-debt balance sheet, Lexaria maintains an extended operational runway to execute its 2026/2027 clinical roadmaps and secure high-margin pharmaceutical licensing agreements.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Alcon’s second quarter 2026 results reflected modest growth supported by a broad-based contribution across its Surgical and Vision Care franchises.
• Sales increased 7% year-over-year to $2.8 billion, with surgical sales rising 7% and Vision Care sales also up 7%.
• Equipment sales, particularly from the UNITY platform, grew 25%, underscoring the commercial success of recent innovations.

• On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of plozasiran in adults with severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) Congress 2026.
• Both studies met their primary endpoint with median triglyceride reductions from baseline of 79% and 81%, respectively.
• In addition, more than 90% of treated patients achieved triglyceride levels <500 mg/dL, which is below the threshold for sHTG.

• Cardinal Health, Inc. concluded fiscal year 2026 with marked financial improvements driven primarily by its Pharmaceutical and Specialty Solutions segment, which benefited from resilient demand and specialty business strength.
• The company reported a 6% increase in total revenue for the fourth quarter to $63.7 billion and a 14% rise for the full year to $254 billion, with operating earnings growing 30% year-over-year and earnings per share increasing by 40% in the quarter.
• Adjusted free cash flow reached $5 billion, reflecting strong operational execution and favorable demand across its portfolio.

• Hims & Hers Health reported second-quarter 2026 results marked by strong growth and continued investment in technology, broader offerings, and international expansion.
• Revenue increased nearly 40% year-over-year to more than $753 million, supported by 300,000 net new subscribers, bringing the total to nearly 3 million.
• U.S. revenue reached $622 million, with domestic growth accelerating to 16% on an expanded weight loss portfolio.

• Zacks Small-Cap Research Note for Lexaria Bioscience Corp. (LEXX)

• AbbVie Acquisition Move: The $10.9 Billion Immunology Gamble Explained AbbVie has moved quickly to deepen its immunology franchise, completing its $10.9 billion acquisition of Apogee Therapeutics on September 3, 2026, after first announcing the transaction during the second quarter.
• The purchase is AbbVie’s largest bolt-on deal since 2019 and adds a portfolio of long-acting biologics targeting atopic dermatitis, respiratory conditions, and other immune-mediated diseases.
• Management has framed Apogee as a strategic addition to a pipeline already anchored by Skyrizi and Rinvoq, with the aim of extending growth into the 2030s and beyond.

• The company has delivered strong sales growth, which is essential for long-term value creation
• The company is very good at generating consistently positive operating cash flow
• The efficiency is very good when looking at the growth in sales relative to the growth in assets